2018 Fiscal Year Final Research Report
Development of cancer suicide gene therapy using RNA trans-splicing technology
| Project/Area Number |
17K19475
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pharmaceutical Sciences and related fields
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
秋田 英万 千葉大学, 大学院薬学研究院, 教授 (80344472)
|
|---|
| Research Collaborator |
Kaneda Atsushi
|
|---|
| Project Period (FY) |
2017-06-30 – 2019-03-31
|
| Keywords | がん分子標的 / 核酸医薬 / ドラッグデリバリー |
|---|
| Outline of Final Research Achievements |
The aim of this study is to develop a cancer gene therapy using RNA trans-splicing technology. We have constructed the therapeutic gene by combining the herpes simplex virus thymidine kinase gene with an RNA trans-splicing molecule targeting cancer-type organic anion transporting polypeptide 1B3. When introduced into human colon cancer cells, the therapeutic gene shows remarkable anti-cancer effects. We have also develop ssPalm-based lipid nanoparticles as a tool for delivery of the therapeutic gene into cancer cells. Collectively, our new cancer gene therapy with RNA trans-splicing technology and ssPalm-based gene delivery system has the potential to become a promising therapeutic option to fight against various cancer types.
|
| Free Research Field |
薬物動態学
|
| Academic Significance and Societal Importance of the Research Achievements |
最新科学を持ってしても未だ治療が困難ながん種は多く、がん死亡数も年々増加傾向にある。これに対し転写リプログラミング核酸医薬は、その効果ががん特異的に発揮されること等従来治療法とは異なる特徴を有し、さらに従来薬抵抗性の難治性がんに対する効果も期待される。したがって本研究成果は、転写リプログラミング核酸医薬開発の礎としてその更なる研究を促し、ひいては難治性がんの克服に貢献する治療法の開発に貢献するものと期待される。
|
